The results showed that, while TAVO412 has a monovalent anti-soluble VEGF-A arm with a slightly weaker binding affinity than bevacizumab, it demonstrated significantly stronger tumor growth inhibition in the model compared to bevacizumab or bevacizumab plus amivantamab at comparable dose levels (data submitted in another manuscript on TNBC). Here, VEGFA is linked to neoplasm.